---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Clinical trials questions"
description: "Clinical trials questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, and Comparative studies. Questions: Do patients live longer on Kisqali plus letrozole vs letrozole alone (MONALEESA-2)? How long did Kisqali plus letrozole delay progression vs letrozole alone (MONALEESA-2)? Who was studied in the Kisqali MONALEESA-2 trial? Do patients live longer on Kisqali plus fulvestrant vs fulvestrant alone (MONALEESA-3)? 8 further questions follow. 12 questions quoted from 8 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Clinical trials questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications](https://www.evicenter.com/medical-information/kisqali).

## Study results

<a id="kisqali-monaleesa-2-survival"></a>

### Do patients live longer on Kisqali plus letrozole vs letrozole alone (MONALEESA-2)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

> “MONALEESA-2 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + letrozole (n=334) vs placebo + letrozole (n=334) in postmenopausal patients with HR+/HER2- mBC who received no prior therapy for advanced disease. OS was a secondary end point; PFS was the primary end point. At a median follow-up of 80 months, mOS was 63.9 months with KISQALI + letrozole (95% CI: 52.4-71.0) vs 51.4 months with placebo + letrozole (95% CI: 47.2-59.7); HR=0.765 (95% CI: 0.628-0.932); P=0.004.<sup>1,2</sup>”

Source: [KISQALI: Efficacy Across Trials | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/efficacy-across-trials#:~:text=MONALEESA%2D2%20was%20a%20randomized%2C%20double%2Dblind%2C,47.2%2D59.7%29%3B%20HR%3D0.765%20%2895%25%20CI%3A%200.628%2D0.932%29%3B)

> “At a median follow-up of 80 months”

Source: [KISQALI: KISQALI® (ribociclib) + AI in 1L Postmenopausal Patients | mBC | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/postmenopausal-with-ai#:~:text=At%20a%20median%20follow%2Dup%20of%2080%20months)

> “At 6 years, the survival rate of patients receiving KISQALI + letrozole was 44% vs 32% with placebo + letrozole<sup>2</sup>”

Source: [KISQALI: KISQALI® (ribociclib) + AI in 1L Postmenopausal Patients | mBC | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/postmenopausal-with-ai#:~:text=At%206%20years%2C%20the%20survival,44%25%20vs%2032%25%20with%20placebo)

<a id="kisqali-monaleesa-2-progression"></a>

### How long did Kisqali plus letrozole delay progression vs letrozole alone (MONALEESA-2)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

> “MONALEESA-2 was a randomized, double-blind, placebo-controlled phase III study of KISQALI (600 mg once daily;  
> 3 weeks on, 1 week off) + letrozole (n=334) or placebo + letrozole (n=334), until disease progression or unacceptable 
> toxicity occurred, in postmenpausal patients with HR+/HER2- mBC who received no prior therapy for advanced disease.  
> OS was a secondary end point; PFS was the primary end point.”

Source: [KISQALI: Support Guide, page 3, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=3)

> “PFS (primary end point)
> For patients receiving KISQALI + letrozole, at a median follow-up of 15 months, mPFS was not reached with KISQALI + 
> letrozole (95% CI: 19.3-NR) vs 14.7 months with placebo + letrozole (95% CI: 13.0-16.5); HR=0.556 (95% CI: 0.429-0.720); 
> P<.0001.”

Source: [KISQALI: Support Guide, page 3, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=3)

> “Progression-Free Survival 
> N = 334 
> N = 334 
> Events (n, %) 
> 93 (27.8) 
> 150 (44.9) 
> Median (months, 95% CI) 
> NR (19.3 – NR) 
> 14.7 (13.0 – 16.5) 
> Hazard Ratio (95% CI) 
> 0.556 (0.429, 0.720) 
> p-value 
> < 0.0001<sup>a</sup>”

Source: [KISQALI: Prescribing information, page 25, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=25)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 19 of the Prescribing Information.

<a id="kisqali-monaleesa-2-design"></a>

### Who was studied in the Kisqali MONALEESA-2 trial?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

> “MONALEESA-2 (NCT01958021) was a randomized (1:1), double-blind, placebo-controlled, multicenter clinical study of 
> KISQALI plus letrozole vs. placebo plus letrozole conducted in postmenopausal women (N = 668) with HR-positive, 
> HER2-negative, advanced breast cancer who received no prior therapy for advanced disease. 
> Participants were randomized to receive either KISQALI plus letrozole or placebo plus letrozole, stratified according to the 
> presence of liver and/or lung metastases. Letrozole 2.5 mg was given orally once daily for 28 days, with either KISQALI 
> 600 mg or placebo orally once daily for 21 consecutive days followed by 7 days off until disease progression or 
> unacceptable toxicity. The major efficacy outcome measure for the study was investigator-assessed progression-free 
> survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.”

Source: [KISQALI: Prescribing information, page 24, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=24)

> “The median age was 62 years (range, 23 to 91) and 45% of patients were older than 65. The majority of patients were White 
> (82%), and all patients had an ECOG performance status of 0 or 1. A total of 47% of patients had received chemotherapy 
> and 51% had received antihormonal therapy in the neoadjuvant or adjuvant setting. Thirty-four percent (34%) of patients 
> had de novo metastatic disease, 21% had bone only disease, and 59% had visceral disease.”

Source: [KISQALI: Prescribing information, page 24, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=24)

<a id="kisqali-monaleesa-3-survival"></a>

### Do patients live longer on Kisqali plus fulvestrant vs fulvestrant alone (MONALEESA-3)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

> “MONALEESA-3 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + fulvestrant (n=484) vs placebo + fulvestrant (n=242) in postmenopausal patients with HR+/HER2- mBC who received no or only 1 line of prior ET for advanced disease. OS was a secondary end point; PFS was the primary end point. Statistical significance was established for the ITT population in the prespecified OS analysis at a median follow-up of 39 months: mOS was not reached with KISQALI + fulvestrant (95% CI: 42.5-NR) vs 40 months with placebo + fulvestrant (95% CI: 37.0-NR); HR=0.724 (95% CI: 0.568-0.924); P=0.00455. In exploratory analyses of the 1L subgroup of patients receiving KISQALI + fulvestrant (n=237) or placebo + fulvestrant (n=128): At a median follow-up of 39 months, mOS was not reached with KISQALI + fulvestrant vs 45.1 months with placebo + fulvestrant; HR=0.70 (95% CI: 0.48-1.02); at a median follow-up of 71 months, mOS was 67.6 months with KISQALI + fulvestrant (95% CI: 59.6-NR) vs 51.8 months with placebo + fulvestrant (95% CI: 40.4-61.2); HR=0.673 (95% CI: 0.504-0.899). Results from the exploratory analyses were not prespecified and were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.<sup>1,3,7,8</sup>”

Source: [KISQALI: Efficacy Across Trials | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/efficacy-across-trials#:~:text=MONALEESA%2D3%20was%20a%20randomized%2C%20double%2Dblind%2C,procedure%20controlling%20for%20type%201)

<a id="kisqali-monaleesa-3-progression"></a>

### How long did Kisqali plus fulvestrant delay progression vs fulvestrant alone (MONALEESA-3)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

> “MONALEESA-3 was a randomized, double-blind, placebo-controlled phase III study of KISQALI (600 mg once daily; 3 weeks 
> on, 1 week off) + fulvestrant (n=484) or placebo + fulvestrant (n=242), until disease progression or unacceptable toxicity 
> occurred, in postmenopausal patients with HR+/HER2- mBC who have received no or only 1 line of prior ET for advanced 
> disease. OS was a secondary end point; PFS was the primary end point.”

Source: [KISQALI: Support Guide, page 4, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=4)

> “PFS (primary end point)
> In the primary analysis at a median follow-up of 20 months, KISQALI significantly improved PFS in the clinical study, with  
> 20.5 months mPFS (95% CI: 18.5-23.5) with KISQALI + fulvestrant vs 12.8 months (95% CI: 10.9-16.3) with fulvestrant  
> (HR=0.593 [95% CI: 0.480-0.732]; P<.0001).”

Source: [KISQALI: Support Guide, page 4, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=4)

> “Progression-Free Survival<sup>a,1</sup> 
> N = 484 
> N = 242 
> Events (n, %) 
> 210 (43.4) 
> 151 (62.4) 
> Median (months, 95% CI) 
> 20.5 (18.5, 23.5) 
> 12.8 (10.9, 16.3) 
> Hazard Ratio (95% CI) 
> 0.593 (0.480, 0.732) 
> p-value<sup>a</sup> 
> < 0.0001”

Source: [KISQALI: Prescribing information, page 29, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=29)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 21 of the Prescribing Information, whose comparator arm is placebo plus fulvestrant.

<a id="kisqali-monaleesa-7-survival"></a>

### Do premenopausal women live longer on Kisqali plus an NSAI and goserelin (MONALEESA-7)?

Applies to: Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

> “MONALEESA-7 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + ET (NSAI or tamoxifen) + goserelin (n=335) vs placebo + ET (NSAI or tamoxifen) + goserelin (n=337) (ITT) in premenopausal patients with HR+/HER2- mBC who received no prior ET for advanced disease. KISQALI is not indicated for concomitant use with tamoxifen. Efficacy results are from a prespecified subgroup analysis of 495 patients who received KISQALI (n=248) or placebo (n=247) with an NSAI + goserelin. OS was a secondary end point; PFS was the primary end point. In the prespecified OS analysis at a median follow-up of 35 months, mOS was not reached with KISQALI + NSAI + goserelin (95% CI: NR-NR) vs 40.7 months with placebo + NSAI + goserelin (95% CI: 37.4-NR); HR=0.699 (95% CI: 0.501-0.976). Statistical significance was established for overall survival in the ITT population; HR=0.71 (95% CI: 0.54-0.95); P=0.00973. At a median follow-up of 54 months (exploratory analysis), mOS was 58.7 months with KISQALI + NSAI + goserelin (95% CI: 48.5-NR) vs 47.7 months with placebo + NSAI + goserelin (95% CI: 41.2-55.4); HR=0.798 (95% CI: 0.615-1.035). Results from the 54-month analysis were not prespecified and were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.<sup>1,4,5,9,10</sup>”

Source: [KISQALI: Efficacy Across Trials | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/efficacy-across-trials#:~:text=MONALEESA%2D7%20was%20a%20randomized%2C%20double%2Dblind%2C,procedure%20controlling%20for%20type%201)

<a id="kisqali-monaleesa-7-progression"></a>

### How long did Kisqali delay progression in premenopausal women (MONALEESA-7)?

Applies to: Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

> “MONALEESA-7 was a randomized, double-blind, placebo-controlled phase III study of KISQALI (600 mg once daily;  
> 3 weeks on, 1 week off) + NSAI or tamoxifen + goserelin (n=335) or placebo + NSAI or tamoxifen + goserelin (n=337),  
> until disease progression or unacceptable toxicity occurred, in premenopausal patients with HR+/HER2- mBC who received 
> no prior ET for advanced disease. KISQALI is not indicated for concomitant use with tamoxifen. Efficacy results are from a 
> prespecified subgroup analysis of 495 patients who received KISQALI (n=248) or placebo (n=247) with an NSAI + goserelin. 
> OS was a secondary end point; PFS was the primary end point.”

Source: [KISQALI: Support Guide, page 5, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=5)

> “PFS (primary end point)
> At a median follow-up of 19 months, KISQALI achieved 27.5 mPFS (95% CI: 19.1-NR) with KISQALI + NSAI + goserelin vs  
> 13.8 months (95% CI: 12.6-17.4) with placebo + NSAI + goserelin (HR=0.569 [95% Cl: 0.436-0.743]).”

Source: [KISQALI: Support Guide, page 5, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=5)

> “Progression-Free Survival<sup>1</sup> 
> N = 248 
> N = 247 
> Events (n, %) 
> 92 (37.1) 
> 132 (53.4) 
> Median (months, 95% CI) 
> 27.5 (19.1, NR) 
> 13.8 (12.6, 17.4) 
> Hazard Ratio (95% CI) 
> 0.569 (0.436, 0.743)”

Source: [KISQALI: Prescribing information, page 27, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=27)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 20 of the Prescribing Information (MONALEESA-7 NSAI subgroup), which gives the medians in months.

<a id="kisqali-monaleesa-7-time-to-chemotherapy"></a>

### How long did Kisqali delay chemotherapy in premenopausal women (MONALEESA-7)?

Applies to: Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

> “At a median follow-up of 54 months, mTTC was 50.9 months with KISQALI + NSAI + goserelin vs 36.0 months with placebo + NSAI + goserelin; HR=0.659 (95% CI: 0.509-0.851)<sup>5</sup>”

Source: [KISQALI: KISQALI® (ribociclib) + AI in 1L Premenopausal | mBC | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/premenopausal-with-ai#:~:text=At%20a%20median%20follow%2Dup%20of%2054%20months%2C,%2B%20goserelin%3B%20HR%3D0.659%20%2895%25%20CI%3A)

> “Time to chemotherapy was evaluated in a post hoc exploratory analysis and was defined as the time from randomization to the beginning of the first chemotherapy after discontinuing study treatment<sup>4</sup>”

Source: [KISQALI: KISQALI® (ribociclib) + AI in 1L Premenopausal | mBC | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/premenopausal-with-ai#:~:text=Time%20to%20chemotherapy%20was%20evaluated,first%20chemotherapy%20after%20discontinuing%20study)

> “There was no prespecified statistical procedure controlling for type 1 error”

Source: [KISQALI: KISQALI® (ribociclib) + AI in 1L Premenopausal | mBC | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/premenopausal-with-ai#:~:text=There%20was%20no%20prespecified%20statistical%20procedure%20controlling%20for%20type%201%20error,-MONALEESA%2D7%20was%20a)

<a id="kisqali-dose-reduction-effectiveness"></a>

### Was survival different after Kisqali dose reduction in MONALEESA trials (post hoc analysis)?

> “Across the 3 phase III MONALEESA clinical trials, overall survival (OS) was maintained for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who required dose reduction of KISQALI. These data are from a time-varying Cox regression analysis of OS by dose reduction. Results are based on a post hoc analysis; efficacy in the placebo comparator arms was not assessed and should be interpreted with caution<sup>1-5</sup>:
>
> In the MONALEESA-2 trial: 62.6% of patients (209/334) had ≥1 dose reduction. Median overall survival (mOS) was 66.0 months for patients with ≥1 dose reduction (95% CI: 57.6-75.7) vs 60.6 months for patients without dose reductions (95% CI: 42.5-79.2); HR=0.87 (95% CI: 0.65-1.18)<sup>1,2</sup>
>
> In the MONALEESA-3 trial: 40.7% of patients (197/484) had ≥1 dose reduction. mOS was not reached for patients with ≥1 dose reduction (95% CI: 43-NR) vs not reached for patients without dose reductions (95% CI: 41.1-NR); HR=0.88 (95% CI: 0.64-1.21)<sup>3,4</sup>
>
> In the MONALEESA-7 trial: 40.7% of patients (101/248) had ≥1 dose reduction. mOS was not reached for patients with ≥1 dose reduction (95% CI: NR-NR) vs not reached for patients without dose reductions (95% CI: NR-NR); HR=0.79 (95% CI: 0.46-1.36)<sup>3,5</sup>”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=Across%20the%203%20phase%20III%20MONALEESA%20clinical%20trials%2C,CI%3A%20NR%2DNR%29%3B%20HR%3D0.79%20%2895%25%20CI%3A)

On the page, select: Does reducing the KISQALI dose affect treatment effectiveness for patients with metastatic breast cancer?

## Subgroup results

<a id="kisqali-age-groups-survival"></a>

### What was Kisqali overall survival by age group (pooled post hoc MONALEESA analysis)?

Applies to: Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

> “An exploratory, pooled, post hoc analysis of the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies: In 1L patients aged <65, at a median follow-up of 71.2 months, mOS was 67.6 months with KISQALI + ET (95% CI: 59.9-NE) vs 51.7 months with placebo + ET (95% CI: 44.9-61.4). In 1L patients aged 65 to 74, at a median follow-up of 77.3 months, mOS was 72.6 months with KISQALI + ET (95% CI: 64.5-NE) vs 59.8 months with placebo + ET (95% CI: 50.0-65.3). In 1L patients aged 75 or older, at a median follow-up of 76 months, mOS was 62.1 months with KISQALI + ET (95% CI: 48.5-70.5) vs 52.8 months with placebo + ET (95% CI: 37.7-63.9). The ≥75 years age group has a small sample size, and data should be interpreted with caution. These results are exploratory and hypothesis-generating; as such, there was no statistical procedure controlling for type 1 error.<sup>1</sup>”

Source: [KISQALI: Data Across Age Groups | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/data-across-age-groups#:~:text=An%20exploratory%2C%20pooled%2C%20post%20hoc%20analysis%20of%20the%20MONALEESA%2D2%2C%20MONALEESA%2D3%2C%20and%20MONALEESA%2D7,-studies%3A%20In%201L)

> “This pooled dataset included a total of 1229 patients across 3 different age groups; 773 (63%) were <65 years, 335 (27%) were 65 to <75 years, and 121 (10%) were ≥75 years.<sup>1</sup>”

Source: [KISQALI: Data Across Age Groups | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/data-across-age-groups#:~:text=This%20pooled%20dataset%20included%20a,and%20121%20%2810%25%29%20were%20%E2%89%A575)

> “The 65 to <75 and ≥75 years age groups consisted of patients from the MONALEESA-2 and MONALEESA-3 studies. The <65 years age group consisted of patients from the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies.<sup>1</sup>”

Source: [KISQALI: Data Across Age Groups | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/data-across-age-groups#:~:text=The%2065%20to%20%3C75%20and,the%20MONALEESA%2D2%2C%20MONALEESA%2D3%2C%20and%20MONALEESA%2D7)

<a id="kisqali-visceral-monaleesa-3"></a>

### What was overall survival with Kisqali plus fulvestrant in visceral metastases (MONALEESA-3)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

> “At a median follow-up of 39 months”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=with%20liver%20metastases-,At%20a%20median%20follow%2Dup%20of%2039%20months)

> “In patients with visceral metastases: Median OS was 41.0 months with KISQALI + fulvestrant (n=293) (95% CI: 38.5-NR) vs 39.4 months with placebo + fulvestrant (n=147) (95% CI: 30.6-42.2); HR=0.804 (95% CI: 0.596-1.083)<sup>13</sup>”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=In%20patients%20with%20visceral%20metastases%3A,CI%3A%2030.6%2D42.2%29%3B%20HR%3D0.804%20%2895%25%20CI%3A)

> “These results were exploratory in nature and should be interpreted with caution due to small n-sizes; as such, there was no prespecified statistical procedure controlling for type 1 error”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=These%20results%20were%20exploratory%20in,controlling%20for%20type%201%20error)

Note: The page presents this subgroup analysis for first- and second-line (1L/2L) postmenopausal patients from MONALEESA-3.

## Comparative studies

<a id="kisqali-right-choice-vs-chemotherapy"></a>

### How did Kisqali compare with chemotherapy in RIGHT Choice patients without visceral crisis?

Applies to: Pre- and perimenopausal women with aggressive HR-positive, HER2-negative advanced or metastatic breast cancer, first-line, with an aromatase inhibitor and goserelin (RIGHT Choice)

> “RIGHT Choice was a randomized, phase II, open-label, multicenter study of KISQALI + AI + goserelin (n=112) vs combination chemotherapy (either docetaxel + capecitabine, paclitaxel + gemcitabine, or capecitabine + vinorelbine) (n=110) in pre- or perimenopausal patients with HR+/HER2- mBC who have aggressive disease. PFS was the primary end point. Efficacy results are from a subgroup analysis of patients with aggressive disease who did not have visceral crisis. In this subgroup, median PFS was 24.0 months with KISQALI + NSAI + goserelin (95% CI: 21.1-NE) vs 12.8 months with combination chemotherapy (95% CI: 8.5-17.5); HR=0.42 (95% CI: 0.25-0.70). Due to the nature of the study, results should be interpreted with caution. These results from a subgroup analysis of patients with aggressive disease who did not have visceral crisis are exploratory and hypothesis-generating; as such, there was no statistical procedure controlling for type 1 error.<sup>2,15,16</sup>”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=RIGHT%20Choice%20was%20a%20randomized%2C,procedure%20controlling%20for%20type%201)

> “KISQALI + AI + goserelin ORR: 60.0% (95% CI: 45.9-73.0)
>
> Combination chemotherapy ORR: 62.3% (95% CI: 49.0-74.4)”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=KISQALI%20%2B%20AI%20%2B%20goserelin%20ORR%3A,ORR%3A%2062.3%25%20%2895%25%20CI%3A%2049.0%2D74.4%29)

> “Overall survival is being evaluated but is ongoing and currently not yet mature.<sup>2</sup>”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=Overall%20survival%20is%20being%20evaluated%20but%20is%20ongoing%20and%20currently%20not%20yet)

Note: All efficacy figures on the page, including the response rates, are from the subgroup of patients without visceral crisis.

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
